- Investor's Business Daily•yesterday
Amgen trumped Regeneron and Sanofi this week as prescriptions of its cholesterol-cutting drug grew.
- Reuters•2 days ago
A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis. The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, Kevzara, citing its ability to reduce the signs and symptoms of rheumatoid arthritis. Sarilumab, the active substance of Kevzara, a treatment for adult patients with moderate to severe rheumatoid arthritis, works by blocking a protein called IL-6, which is associated with inflammation.
- Reuters•3 days ago
Up to 4,100 children in France suffered major malformations in the womb after their mothers took a treatment against epilepsy and bipolar disorders known as valproate between 1967 and 2016, France's drug regulator said. Valproate, which has been manufactured in France by Sanofi under the brand Depakine for epilepsy and Depakote and Depamide for bipolar disorders, is also believed to cause slow neurological development, ANSM said on Thursday.
SAN.PA : Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||82.29 - 83.09|
|52 Week Range||62.50 - 86.05|
|PE Ratio (TTM)||22.68|
|Dividend & Yield||3.35 (3.72%)|
|1y Target Est||N/A|